World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2025
Volume: 4; Issue: 4
Page: 109-119

EMERGING MONOCLONAL ANTIBODIES BASED TARGETED THERAPIES IN ONCOLOGY: MECHANISMS, CHALLENGES, AND FUTURE DIRECTIONS

Sakshi K. Shahane[*1], Sujata S. Ilag[2], Nikita S. Lahane[3], Sakshi D. Vanarse[4], Supriya B. Khedkar[5]

[1,2,3,4,5]Department of B. Pharmacy, Pravara Rural Education Society's Institute of Pharmacy, Loni, Maharashtra, India.

Article Received: 08 June 2025 | | Article Revised: 29 June 2025 | | Article Accepted: 20 July 2025

***Corresponding Author: Sakshi K. Shahane**
Department of B. Pharmacy, Pravara Rural Education Society's Institute of Pharmacy, Loni, Maharashtra, India.
DOI: https://doi.org/10.5281/zenodo.16633188

How to cite this Article: Sakshi K. Shahane, Sujata S. Ilag, Nikita S. Lahane, Sakshi D. Vanarse, Supriya B. Khedkar (2025) EMERGING MONOCLONAL ANTIBODIES BASED TARGETED THERAPIES IN ONCOLOGY: MECHANISMS, CHALLENGES, AND FUTURE DIRECTIONS. World Journal of Pharmaceutical Science and Research, 4(4), 109-119. https://doi.org/10.5281/zenodo.16633188

ABSTRACT

Monoclonal antibodies (mAbs) have revolutionized oncology by offering highly specific therapeutic options that target tumor-associated antigens, minimizing damage to healthy tissues. These biologics exert their effects through various mechanisms including receptor blockade, immune system modulation, induction of apoptosis, and targeted delivery of cytotoxic agents. The development of next-generation antibody formats such as bispecific antibodies, antibody-drug conjugates (ADCs), nanobodies, and fusion proteins has further enhanced their efficacy and broadened clinical applications. Furthermore, advances in artificial intelligence (AI) and bioinformatics are paving the way for personalized antibody-based therapies tailored to individual tumor profiles. Despite their growing clinical utility, mAb-based therapies face several challenges that limit their broader implementation. These include tumor heterogeneity, development of resistance pathways, immune evasion tactics by cancer cells, limited tumor penetration, and high manufacturing costs. Additionally, adverse effects such as cytokine release syndrome and immunogenicity present further clinical hurdles. This review provides a comprehensive overview of monoclonal antibody mechanisms of action, current therapeutic strategies, emerging innovations, and the key biological and logistical challenges encountered in their development and use. Future directions highlight the integration of computational tools for antibody design, combination therapies with immune checkpoint inhibitors, and strategies to improve global access and affordability. With continued innovation and interdisciplinary collaboration, monoclonal antibody-based therapies hold the potential to significantly transform the landscape of cancer treatment by offering more effective, safer, and patient-specific options.

KEYWORDS: Monoclonal Antibodies; Cancer Immunotherapy; Bispecific Antibodies; Antibody-Drug Conjugates; Tumor Microenvironment; Personalized Medicine; Artificial Intelligence in Oncology.

1. INTRODUCTION

Monoclonal antibodies (mAbs) represent one of the most transformative classes of biotherapeutic agents developed over the past several decades. Derived from a single clone of B cells, these antibodies are highly specific to a single epitope and have been engineered for diverse therapeutic purposes. Their precision in targeting specific antigens has revolutionized the treatment of various diseases, particularly in oncology, autoimmune disorders, and infectious diseases. The journey of monoclonal antibody development began in 1975 when Köhler and Milstein introduced the hybridoma technology, allowing for the production of mAbs in laboratory settings by fusing antibody-producing B cells with immortal myeloma cells. This innovation enabled the generation of murine monoclonal antibodies, which laid the foundation for further advancements. However, murine antibodies triggered immunogenic responses in humans, leading to the development of chimeric, humanized, and ultimately fully human antibodies using recombinant DNA technology and phage display systems.

Over the past few decades, mAbs have become pivotal in managing immune-mediated disorders such as rheumatoid arthritis, psoriasis, multiple sclerosis, and inflammatory bowel diseases. By modulating specific components of the immune system, mAbs can suppress aberrant immune responses without broadly compromising immune function. This targeted approach enhances therapeutic efficacy while reducing adverse effects compared to conventional immunosuppressants.

Today, the field of monoclonal antibody therapeutics continues to evolve rapidly with the introduction of bispecific antibodies, antibody-drug conjugates, and Fc-engineered variants. These innovations not only broaden the clinical applications of mAbs but also exemplify the synergy between molecular biology, immunology, and translational medicine. As our understanding of disease mechanisms deepens, the scope and sophistication of monoclonal antibody therapies are expected to grow correspondingly.



Figure 1. 1 Structure and Production of Monoclonal Antibodies.

(Created by author using AI assistance, 2025)



Figure 1. 2 Historical Development of Monoclonal Antibodies.

(Created by author using AI assistance, 2025)

a. Mechanism of action



Figure 1.3: Mechanisms of action of monoclonal antibodies in cancer therapy.
(Created by author using AI assistance, 2025)

i. **Cytokine Neutralization –** Neutralizing antibodies bind cytokines (e.g., TNF-α, IL-6), blocking signaling and reducing inflammation.

ii. **Immune Checkpoint Blockade –** Antibodies block inhibitory pathways (e.g., PD-1/PD-L1), reactivating T-cells to attack tumor cells.

iii. **Pathogenic Cell Depletion –** Antibodies bind antigens (e.g., CD20), inducing cell death via ADCC, CDC, or apoptosis.

iv. **Fc Engineering –** Modified Fc regions enhance interaction with immune cells, improving therapeutic efficacy.

v. **Receptor Blockade and Signal Inhibition-** Monoclonal antibodies can block ligand-receptor interactions on the surface of cancer cells, thereby inhibiting downstream signaling pathways that promote proliferation, angiogenesis, and survival. For example, antibodies targeting EGFR or HER2 prevent activation of mitogenic pathways such as MAPK and PI3K/AKT.

vi. **Antibody-Drug Conjugate (ADC) Mediated Cytotoxicity**- In ADCs, monoclonal antibodies are linked to potent cytotoxic drugs. Once the antibody binds to the tumor-specific antigen, the complex is internalized, and the cytotoxic agent is released inside the cancer cell, leading to apoptosis while sparing healthy tissues.

vii. **Immune Cell Redirection through Bispecific Antibodies-** Bispecific monoclonal antibodies are engineered to simultaneously bind tumor antigens and immune cell receptors (e.g., CD3 on T-cells), effectively redirecting immune effector cells to tumor sites. This close interaction enhances immune-mediated tumor cell killing.

2. METHODOLOGY

a. Therapeutic Applications

This review paper was developed using a **systematic and comprehensive literature survey** to gather, analyze, and synthesize current knowledge regarding monoclonal antibody (mAb)-based targeted therapies in oncology. A structured approach was employed to ensure that the content is both scientifically rigorous and relevant to the evolving landscape of cancer immunotherapy.

The primary sources of literature were **international peer-reviewed journals**, **clinical trial databases**, and **official pharmaceutical research platforms**. Data were retrieved from reputed scientific indexing databases such as **PubMed, ScienceDirect, Web of Science, Scopus, SpringerLink, and Google Scholar**. The review focused on articles published between **January 2010 and May 2024**, ensuring the inclusion of the most recent and impactful discoveries in the field. The search strategy incorporated combinations of keywords and Boolean operators using terms such as *"monoclonal antibodies," "targeted cancer therapy," "immune checkpoint inhibitors," "bispecific antibodies," "antibody-drug conjugates (ADCs)," "tumor microenvironment," "nanobody technology,"* and *"AI-based antibody design."*

Selection criteria included original research articles, systematic reviews, meta-analyses, regulatory reports, clinical guidelines, and Phase I–IV clinical trial results. Studies were included based on their relevance to therapeutic mechanisms, resistance pathways, pharmacological advances, clinical efficacy, and safety profiles. Non-English publications, unrelated topics, duplicated records, and non-peer-reviewed sources (e.g., blogs, Wikipedia, advertisements) were excluded from the review. Data extraction was performed manually, emphasizing the thematic relevance and scientific accuracy of the selected studies. Articles were categorized under key thematic areas: (i) Mechanisms of Action, (ii) Therapeutic Applications, (iii) Resistance Mechanisms, (iv) Adverse Effects, (v) Technological Advancements (e.g., nanobodies, fusion proteins), and (vi) Future Directions. Cross-referencing and citation tracing were also used to expand on foundational concepts and track the evolution of antibody-based oncology treatments.

To ensure objectivity and minimize bias, all articles were independently reviewed and evaluated based on their impact factor, citation frequency, journal reputation, and relevance to the topic. Emphasis was placed on research from high-impact journals and clinical studies involving FDA or EMA-approved monoclonal antibody therapies. This methodology ensured a critical, well-rounded, and scientifically sound analysis of monoclonal antibody innovations in cancer therapy, forming the foundation of this review's insights and future perspectives.

3. CURRENT LANDSCAPE OF MONOCLONAL ANTIBODY THERAPIES

3.1 Therapeutic Applications of Monoclonal Antibodies in Oncology:

Monoclonal antibodies (mAbs) are highly specific biologics engineered to target unique antigens on cancer cells. Their application in oncology has significantly improved treatment precision while minimizing damage to healthy cells. Below are key mAb therapies and their targets:

1. Trastuzumab (HER2-positive breast cancer)

Trastuzumab specifically binds to the human epidermal growth factor receptor 2 (HER2), a protein overexpressed in certain breast and gastric cancers. By inhibiting HER2 signaling, it prevents tumor growth and promotes immune-mediated cell destruction.

2. Rituximab (B-cell lymphomas and leukemia)

Rituximab targets CD20, a surface antigen found on B lymphocytes. It is commonly used in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. It initiates cell death via antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated lysis.

3. Panitumumab (Colorectal cancer)

This fully human mAb binds to the epidermal growth factor receptor (EGFR), blocking its activation and thereby halting tumor cell proliferation in colorectal carcinoma.

4. Atezolizumab (Immune checkpoint inhibitor)

Atezolizumab targets PD-L1, restoring T-cell activity against cancer cells. It's widely used in colorectal, lung, and urothelial cancers.

5. Ipilimumab and Nivolumab (Melanoma and lung cancer)

These antibodies block CTLA-4 and PD-1, respectively, lifting inhibitory checkpoints and activating cytotoxic T lymphocytes. Their combination has shown synergistic effects in treating advanced melanoma.

6. Ramucirumab (Anti-angiogenic therapy)

Ramucirumab binds VEGFR-2, a receptor that promotes new blood vessel formation. By blocking this pathway, it deprives tumors of oxygen and nutrients, particularly in gastric and colorectal cancers.

7. Daratumumab (Multiple myeloma)

This mAb targets CD38, a glycoprotein found on malignant plasma cells. It disrupts tumor growth and enhances immune-mediated clearance in patients with multiple myeloma.



Figure 3.1: Therapeutic monoclonal antibodies and their molecular targets in oncology.

(Created by author using AI assistance, 2025)

3.2 Resistance Mechanisms to Monoclonal Antibody Therapy

Despite their efficacy, monoclonal antibodies face significant resistance challenges due to tumor adaptation. Key resistance mechanisms include:

1. **Antigen Loss or Mutation**: Tumor cells may downregulate or genetically alter the target antigen, such as HER2 or CD20, reducing antibody binding and rendering therapy ineffective.

2. **Activation of Alternative Signaling Pathways**: Cancer cells can bypass blocked pathways by activating compensatory cascades like PI3K/AKT or RAS/RAF/MEK, maintaining their proliferation and survival despite receptor blockade.
3. **Impaired Immune Effector Function**: Reduced functionality of immune cells involved in ADCC or T-cell exhaustion may hinder the immune-mediated killing induced by mAbs, especially in heavily immunosuppressed tumor microenvironments.
4. **Immunosuppressive Tumor Microenvironment (TME)**: The TME may harbor regulatory T-cells (Tregs), myeloid-derived suppressor cells (MDSCs), or inhibitory cytokines, all of which can dampen the immune response and protect tumor cells.
5. **Increased Antigen Shedding or Clearance**: Tumor cells may release soluble forms of target antigens into circulation, which bind mAbs before they reach the tumor, reducing their efficacy. Additionally, accelerated drug clearance can reduce therapeutic concentrations.

3.3 Adverse Effects and Safety Challenges

While monoclonal antibodies are considered safer than conventional chemotherapy, they are associated with specific adverse effects that must be monitored.

1. **Infusion-Related Reactions (IRRs)**: Common during initial infusions, especially with chimeric or murine-derived antibodies. Symptoms may include fever, chills, hypotension, rash, and bronchospasm. Pre-medication with corticosteroids or antihistamines is often used to prevent severe reactions.
2. **Cytokine Release Syndrome (CRS)**: Occurs primarily with T-cell engaging antibodies (e.g., bispecifics like blinatumomab). Massive cytokine release can lead to systemic inflammation, organ dysfunction, hypotension, and respiratory distress. Management includes supportive care and IL-6 inhibitors like tocilizumab.
3. **Immunogenicity and Anti-Drug Antibody (ADA) Formation**: The immune system may recognize therapeutic antibodies as foreign and generate neutralizing antibodies against them. This can reduce therapeutic efficacy or trigger allergic and hypersensitivity reactions.
4. **Off-Target Effects**: Unintentional binding to antigens on normal cells may lead to autoimmune-like symptoms such as skin rash, diarrhea, or organ inflammation. Humanized or fully human mAbs are designed to minimize such risks.
5. **Progressive Multifocal Leukoencephalopathy (PML)**: A rare but life-threatening brain infection caused by reactivation of JC virus, particularly associated with natalizumab. This complication underscores the importance of patient monitoring during treatment.

3.4 Next-Generation Monoclonal Antibodies

Innovations in antibody engineering have led to next-generation therapies designed to enhance efficacy, reduce toxicity, and overcome resistance.

1. Bispecific Antibodies (BsAbs)

- **Definition**: Engineered antibodies with dual specificity — each arm binds a different antigen.
- **Mechanism**: One arm binds to a tumor antigen; the other engages immune effector cells (like CD3 on T-cells), redirecting them to kill cancer cells.
- **Example**: **Blinatumomab** targets CD19 (on B-cells) and CD3 (on T-cells) in B-cell leukemia.

- **Advantages**: Improved immune activation, precise targeting, and reduced escape potential.

2. Antibody-Drug Conjugates (ADCs)

- **Definition**: Monoclonal antibodies chemically linked to potent cytotoxic drugs.
- **Mechanism**: The mAb binds to the tumor cell, is internalized, and releases the cytotoxic drug directly into the tumor, limiting damage to normal cells.
- **Example**: **Trastuzumab emtansine (T-DM1)** for HER2-positive breast cancer.
- **Structure**: Consists of a targeting mAb, a linker (cleavable inside the cell), and a cytotoxic payload.

3. Nanobodies and Fusion Proteins

- **Nanobodies**: Single-domain antibody fragments derived from camelid heavy-chain-only antibodies. Their small size (~15 kDa) allows deep tissue penetration and excellent stability.
- *Example*: **Caplacizumab**, a nanobody targeting von Willebrand factor.
- **Fusion Proteins**: Combine the Fc region of antibodies with biologically active ligands or enzymes.
- *Example*: **Etanercept**, a TNF receptor-Fc fusion protein used in rheumatoid arthritis.
- **Benefits**: Enhanced bioavailability, prolonged half-life, and targeted activity.

4. Personalized Antibody Therapy

- **Concept**: Tailoring antibody therapies based on individual genomic, proteomic, or transcriptomic tumor profiles.
- **Technologies**: Use of **AI algorithms**, **B-cell receptor sequencing**, and **neoantigen prediction** to design customized antibodies.
- **Example**: Personalized neoantigen-specific mAbs in melanoma or colorectal cancer.
- **Future Potential**: Could integrate with **CRISPR gene-editing**, **mRNA platforms**, and **predictive omics** to provide individualized, highly specific therapies.

Next-Generation Monoclonal Antibodies

Type of Next-Gen mAb	Description & Features	Example(s)
Bispecific Antibodies (BsAbs)	Bind two different targets (e.g. tumor + immune cell)	Blinatumomab (CD19 x CD3)
Antibody-Drug Conjugates (ADC)	mAbs linked with cytotoxic drugs – direct killing of cancer cells	Trastuzumab emtansine (T–DM1)
Immune Checkpoin Inhibitors	Block immune inhibitors like PD-1/PD-L1 or CTLA-4 to activate T-cells	Nivolumab Atezolizumab
Glycoengineered mAbs	Modified sugar chains to enhance ADCC	Obinutuzumab
Nanobodies (VHH fragments)	Small-sized antibody fragments with better tumor penetration	In research, e.g., Caplacizumab

Figure 3.2: Classification of next-generation monoclonal antibodies (mAbs) based on design features and therapeutic function.

(Created by author using AI assistance, 2025)

4. DISCUSSION & ANALYSIS

4.1 Future Perspectives and Challenges

Monoclonal antibody (mAb) therapies have demonstrated significant clinical success in oncology, yet several scientific, economic, and regulatory challenges must be addressed to optimize their long-term impact. This section outlines emerging trends, obstacles, and future directions that will shape the next generation of mAb-based treatments.

a. AI in Antibody Discovery and Optimization

i. **Role and Advancements:** Artificial Intelligence (AI) is rapidly transforming the field of therapeutic antibody development by streamlining early-stage design and reducing the timeline for drug discovery. Deep learning algorithms are capable of predicting antigen-binding sites (epitopes), modeling antibody-antigen interactions, and evaluating structural stability. These computational tools significantly accelerate lead identification and help optimize binding affinity, pharmacokinetics, and immunogenicity profiles.

ii. **Key Technologies and Tools**

- **AlphaFold**: Predicts 3D protein structures with high accuracy.
- **DeepAb and AbLang**: Used for de novo antibody design and language modeling of antibody sequences.
- **BioPhi**: Supports structure-function analysis of antibodies and epitope mapping.

iii. **Clinical Impact:** AI allows rapid generation of high-affinity antibodies tailored to specific tumor targets. It can also predict potential resistance mechanisms through simulation of escape mutations, enabling preemptive design modifications.

iv. **Challenges**

- Limited explainability of AI predictions ("black-box" models).
- Regulatory agencies lack standardized pathways for evaluating AI-generated biologics.
- Dependence on quality of training datasets, which may not cover diverse populations or rare cancers.

5. Case Example in Oncology: AI-assisted workflows have been applied in the design of optimized anti-HER2 and anti-EGFR monoclonal antibodies, offering potential improvements in therapeutic performance in breast and colorectal cancers.

Table 4.1: Comparison of Traditional vs. Next-Generation Monoclonal Antibodies.

Feature	Traditional mAbs (e.g., Rituximab)	Next-Generation mAbs (e.g., Blinatumomab, T-DM1)
Structure	Single specificity IgG	Bispecific, ADCs, Nanobodies
Mechanism of Action	Receptor blockade, ADCC, CDC	Dual targeting, payload delivery, enhanced effector functions
Molecular Size	~150 kDa	Varies (e.g., Nanobodies ~15 kDa)
Tissue Penetration	Moderate	Improved (especially nanobodies)
Immune Engagement	Indirect	Direct T-cell recruitment (BsAbs)
Clinical Examples	Rituximab, Trastuzumab	Blinatumomab, Trastuzumab

2. Cost-Effectiveness and Global Access

The Economic Burden: Monoclonal antibodies remain among the most expensive classes of therapeutics due to complex upstream and downstream production steps, including mammalian cell culture systems (e.g., CHO cells), purification, and quality control processes. These factors restrict availability in low- and middle-income countries (LMICs) and lead to financial toxicity even in high-income settings.

a. Impact on Healthcare Equity

i. Limited patient access to life-saving treatments in LMICs.

ii. Out-of-pocket expenses burdening patients in countries with partial or no insurance coverage.

iii. Delays in market entry due to patent and regulatory exclusivities.

b. Proposed Solutions

i. **Biosimilars**: Affordable alternatives such as **Trastuzumab-dkst** have improved access in select markets.

ii. **CHO-free Expression Systems**: Use of plant, yeast, or microbial platforms to reduce manufacturing costs.

iii. **Pay-for-Performance Models**: Payment tied to therapeutic success, increasingly adopted by national health services.

iv. **Technology Transfer Initiatives**: Collaborations with LMIC-based manufacturers for localized production and distribution.

c. Future Outlook: Global mAb access may improve through WHO prequalification programs, pooled procurement mechanisms, and open-source technology platforms.

4. Pandemic Preparedness and mAbs Beyond Oncology

Lessons from COVID-19: The global response to COVID-19 highlighted the potential of monoclonal antibodies to be rapidly designed, tested, and deployed in emergent health crises. mAbs like **Sotrovimab** and **Bamlanivimab** were developed and distributed within months, showcasing scalable production via phage display and hybridoma platforms.

a. Advantages in Infectious Disease Preparedness

i. Rapid adaptability to novel pathogens.

ii. Potential to stockpile effective antibodies for outbreak-prone viruses.

iii. Long shelf-life with proper formulation and storage.

b. Limitations and Challenges

i. High production costs and distribution logistics.

ii. Mutational escape variants can rapidly reduce efficacy, necessitating real-time surveillance and redesign.

iii. Competition with vaccines in public health planning.

c. Future Strategies

i. Development of **broadly neutralizing antibodies (bnAbs)** targeting conserved viral epitopes.

ii. Establishment of **modular mAb platforms** for fast reprogramming across diseases.

iii. Application in virus-driven cancers like **HPV** (cervical cancer) and **EBV** (nasopharyngeal carcinoma).

5. CONCLUSION

Monoclonal antibody-based therapies have undeniably reshaped modern oncology by offering precise, targeted, and increasingly personalized treatment options for a wide range of malignancies. From their origins in hybridoma technology to the development of next-generation platforms such as bispecific antibodies, ADCs, nanobodies, and AI-guided personalized immunotherapies, mAbs continue to evolve at a rapid pace. Their mechanisms of action—including immune checkpoint inhibition, cytokine neutralization, and direct cytotoxicity—have demonstrated significant clinical efficacy across multiple cancer types. However, challenges such as tumor heterogeneity, resistance mechanisms, high manufacturing costs, and limited accessibility, particularly in low- and middle-income countries, must be addressed. Innovations in bioengineering, artificial intelligence, and global collaboration are paving the way for more affordable, accessible, and effective therapies. As we move forward, the integration of monoclonal antibody

technologies with genomics, proteomics, and machine learning holds the promise of revolutionizing cancer treatment. Continued efforts in translational research, regulatory harmonization, and ethical considerations will be critical to ensuring the safe and equitable deployment of these advanced biologics. Ultimately, monoclonal antibodies are poised not only to enhance cancer care but to redefine the landscape of precision medicine.

6. ACKNOWLEDGEMENT

The author(s) would like to express sincere gratitude to all the researchers and scholars whose work has contributed significantly to the development of this review. Their scientific findings and clinical insights have been instrumental in shaping the current understanding of monoclonal antibody-based therapies in oncology. Special thanks are extended to the faculty and mentors of **Pravara Rural Education Society's Institute of pharmacy Loni**, whose continuous guidance, encouragement, and critical feedback have greatly enhanced the quality and depth of this manuscript. We also acknowledge the valuable contributions of publicly accessible databases and journals that provided access to high-quality literature and research material essential for this review. Finally, the author(s) appreciate the support and cooperation of peers, friends, and family members who have motivated us throughout the writing and compilation of this paper.

7. REFERENCES

1. Abbas AK, Lichtman AH, Pillai S. *Cellular and Molecular Immunology*. 10th ed. Elsevier; 2022.
2. Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the “high-hanging fruit.” *Nat Rev Drug Discov*, 2018; 17(3): 197–223.
3. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. *Br J Pharmacol*, 2009; 157(2): 220–33.
4. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. *Nat Rev Immunol*, 2010; 10(5): 301–16.
5. Dahan R, Barnhart BC, Ravetch JV. Therapeutic antibody effector functions: the importance of Fc receptor engagement in vivo. *Nat Rev Immunol*, 2016; 16(12): 724–37.
6. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. *mAbs*, 2015; 7(1): 9–14.
7. Edwards JC, et al. Efficacy of B cell–targeted therapy with rituximab in patients with rheumatoid arthritis. *N Engl J Med*, 2004; 350(25): 2572–81.
8. Emery P, et al. Tocilizumab in patients with rheumatoid arthritis: OPTION study. *Lancet*, 2008; 371(9617): 987–97.
9. Furie R, et al. Two-year, randomized, controlled trial of belimumab in systemic lupus erythematosus. *Arthritis Rheum*, 2011; 63(12): 3918–30.
10. Hafeez U, Gan HK, Scott AM. Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. *Curr Opin Pharmacol*, 2020; 52: 56–65.
11. Kaplon H, Reichert JM. Antibodies to watch in 2021. *mAbs*, 2021; 13(1): 1860476.
12. Mullard A. FDA approves 100th monoclonal antibody product. *Nat Rev Drug Discov*, 2021; 20(7): 491–5.
13. Nagpal P, Singh D. Bispecific antibodies: a review of development and clinical success. *BioDrugs*, 2020; 34(5): 543–58.
14. Newman MJ, Benani DJ. A review of blinatumomab: a novel immunotherapy. *J Oncol Pharm Pract*, 2006; 12(4): 193–200.

15. Polman CH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Me*, 2006; 354(9): 899–910.
16. Reichert JM. Antibodies to watch in 2017. *mAbs*, 2017; 9(2): 167–81.
17. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. *Nat Rev Cancer*, 2012; 12(4): 278–87.
18. Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer. *N Engl J Med*, 2001; 344(11): 783–92.
19. Thie H, Hust M. Phage display derived human antibodies in clinical development and therapy. *mAbs*, 2020; 12(1): 1729683.
20. Topp MS, et al. Targeted therapy with the bispecific T-cell engager blinatumomab in patients with relapsed or refractory B-precursor ALL. *Lancet Oncol*, 2015; 16(1): 57–66.
21. van der Woning B, et al. Emerging antibody therapeutics in clinical trials. *Front Immuno*, 2022; 13: 832140.
22. van der Neut Kolfschoten M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. *Science*, 2007; 317(5844): 1554–7.
23. Waldmann TA. Immunotherapy: past, present and future. *Nat Med*, 2003; 9(3): 269–77.
24. Wang J, et al. Challenges and opportunities in developing antibody-drug conjugates. *Acta Pharm Sin B*, 2019; 9(5): 774–86.
25. Weiner GJ. Building better monoclonal antibody-based therapeutics. *Nat Rev Cancer*, 2015; 15(6): 361–70.
26. Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. *Nat Rev Drug Discov*, 2017; 16(3): 181–202.
27. Zettlitz KA, et al. Engineering monoclonal antibodies for imaging and therapy. *Clin Cancer Res*, 2022; 28(3): 521–31.